RNA Therapeutics

RNA therapeutics developer, Ribometrix, and Vertex Pharmaceuticals Incorporated, NASDAQ:VRTX, have announced that the companies have entered into a strategic collaboration to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases.

The collaboration will combine Ribometrix’s proprietary discovery platform for identifying and optimizing small molecule therapeutics that modulate RNA function by targeting three-dimensional, 3D, RNA structures with Vertex's scientific, clinical and regulatory capabilities for up to three therapeutic programs, including one ongoing discovery program from Ribometrix.

Ribometrix is based on technologies invented in the UNC Chemistry Department, and was founded by Professor Kevin Weeks and Dr. Katie Warner, a former undergraduate in the department. The company is based in Durham, North Carolina, and currently employs over thirty people, about half of whom have ties to UNC.